CA3002505A1 - Method for the enrichment of cell free nucleosomes - Google Patents
Method for the enrichment of cell free nucleosomes Download PDFInfo
- Publication number
- CA3002505A1 CA3002505A1 CA3002505A CA3002505A CA3002505A1 CA 3002505 A1 CA3002505 A1 CA 3002505A1 CA 3002505 A CA3002505 A CA 3002505A CA 3002505 A CA3002505 A CA 3002505A CA 3002505 A1 CA3002505 A1 CA 3002505A1
- Authority
- CA
- Canada
- Prior art keywords
- histone
- nucleosomes
- sample
- binding agent
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010047956 Nucleosomes Proteins 0.000 title claims abstract description 342
- 210000001623 nucleosome Anatomy 0.000 title claims abstract description 342
- 238000000034 method Methods 0.000 title claims abstract description 155
- 210000004027 cell Anatomy 0.000 title claims abstract description 112
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 242
- 108010033040 Histones Proteins 0.000 claims abstract description 218
- 102000006947 Histones Human genes 0.000 claims abstract description 161
- 239000011230 binding agent Substances 0.000 claims abstract description 132
- 239000000523 sample Substances 0.000 claims abstract description 108
- 239000012472 biological sample Substances 0.000 claims abstract description 51
- 201000011510 cancer Diseases 0.000 claims description 85
- 230000001973 epigenetic effect Effects 0.000 claims description 81
- 238000003018 immunoassay Methods 0.000 claims description 56
- 230000004048 modification Effects 0.000 claims description 44
- 238000012986 modification Methods 0.000 claims description 44
- 238000004458 analytical method Methods 0.000 claims description 32
- 102000001708 Protein Isoforms Human genes 0.000 claims description 30
- 108010029485 Protein Isoforms Proteins 0.000 claims description 30
- 238000004949 mass spectrometry Methods 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 23
- 108010077544 Chromatin Proteins 0.000 claims description 21
- 210000003483 chromatin Anatomy 0.000 claims description 21
- 210000002381 plasma Anatomy 0.000 claims description 21
- 239000000090 biomarker Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 18
- 210000001124 body fluid Anatomy 0.000 claims description 18
- 210000003040 circulating cell Anatomy 0.000 claims description 18
- 238000001261 affinity purification Methods 0.000 claims description 17
- 102100039869 Histone H2B type F-S Human genes 0.000 claims description 15
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims description 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 102100037487 Histone H1.0 Human genes 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 101001026554 Homo sapiens Histone H1.0 Proteins 0.000 claims description 9
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000001712 DNA sequencing Methods 0.000 claims description 6
- 101710195387 Histone H3.2 Proteins 0.000 claims description 6
- 230000002357 endometrial effect Effects 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 230000001323 posttranslational effect Effects 0.000 claims description 6
- -1 variant Proteins 0.000 claims description 6
- 102100033636 Histone H3.2 Human genes 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 210000003802 sputum Anatomy 0.000 claims description 5
- 208000024794 sputum Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 102100034535 Histone H3.1 Human genes 0.000 claims description 4
- 102100034536 Histone H3.1t Human genes 0.000 claims description 4
- 101710195400 Histone H3.3 Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 101710195388 Histone H3.1 Proteins 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 238000007847 digital PCR Methods 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 230000002175 menstrual effect Effects 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 102000017286 Histone H2A Human genes 0.000 claims 1
- 108050005231 Histone H2A Proteins 0.000 claims 1
- 101710103773 Histone H2B Proteins 0.000 claims 1
- 102100021639 Histone H2B type 1-K Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 239000000243 solution Substances 0.000 description 31
- 201000010099 disease Diseases 0.000 description 28
- 239000011324 bead Substances 0.000 description 25
- 238000001514 detection method Methods 0.000 description 24
- 230000035772 mutation Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000007790 solid phase Substances 0.000 description 16
- 239000010839 body fluid Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 206010009944 Colon cancer Diseases 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 12
- 238000013019 agitation Methods 0.000 description 12
- 238000002955 isolation Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000004087 circulation Effects 0.000 description 11
- 239000012160 loading buffer Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 239000011534 wash buffer Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000007069 methylation reaction Methods 0.000 description 9
- 238000010187 selection method Methods 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 238000007885 magnetic separation Methods 0.000 description 8
- 230000011987 methylation Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000004481 post-translational protein modification Effects 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 101710113436 GTPase KRas Proteins 0.000 description 5
- 230000002583 anti-histone Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 241000220259 Raphanus Species 0.000 description 3
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 238000003450 affinity purification method Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- OHDRQQURAXLVGJ-AXMZSLBLSA-N azane;(2z)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-AXMZSLBLSA-N 0.000 description 3
- 230000003822 cell turnover Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 230000008836 DNA modification Effects 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 2
- 102000012060 Septin 9 Human genes 0.000 description 2
- 108050002584 Septin 9 Proteins 0.000 description 2
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000117 blood based biomarker Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 101100482081 Agrobacterium vitis (strain S4 / ATCC BAA-846) iaaM gene Proteins 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100170834 Arabidopsis thaliana ERDJ3A gene Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 108091030081 DNA N(4)-methylcytosine Proteins 0.000 description 1
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 1
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 1
- 102100027489 Helicase-like transcription factor Human genes 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101710192083 Histone H1.0 Proteins 0.000 description 1
- 102100023919 Histone H2A.Z Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 description 1
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 1
- 101001081105 Homo sapiens Helicase-like transcription factor Proteins 0.000 description 1
- 101000905054 Homo sapiens Histone H2A.Z Proteins 0.000 description 1
- 101100110004 Homo sapiens PYCARD gene Proteins 0.000 description 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 1
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 description 1
- 101000843236 Homo sapiens Testis-specific H1 histone Proteins 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 1
- 101100123313 Mus musculus H1.8 gene Proteins 0.000 description 1
- 101100095608 Mus musculus Serinc3 gene Proteins 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Nonanedioid acid Natural products OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 101150045565 Socs1 gene Proteins 0.000 description 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 1
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 description 1
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 description 1
- 102100031010 Testis-specific H1 histone Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006329 citrullination Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000009635 nitrosylation Effects 0.000 description 1
- 230000006610 nonapoptotic cell death Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000029586 nucleosome binding proteins Human genes 0.000 description 1
- 108091009242 nucleosome binding proteins Proteins 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 101150116154 tms1 gene Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518665.3 | 2015-10-21 | ||
| GBGB1518665.3A GB201518665D0 (en) | 2015-10-21 | 2015-10-21 | Method for enrichment of cell free nucleosomes |
| PCT/GB2016/053305 WO2017068371A1 (en) | 2015-10-21 | 2016-10-21 | Method for the enrichment of cell free nucleosomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3002505A1 true CA3002505A1 (en) | 2017-04-27 |
Family
ID=55131411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3002505A Pending CA3002505A1 (en) | 2015-10-21 | 2016-10-21 | Method for the enrichment of cell free nucleosomes |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10746746B2 (enExample) |
| EP (2) | EP3365684B1 (enExample) |
| JP (1) | JP6831841B2 (enExample) |
| CN (1) | CN108603884A (enExample) |
| AU (1) | AU2016341501B2 (enExample) |
| CA (1) | CA3002505A1 (enExample) |
| DK (1) | DK3365684T3 (enExample) |
| ES (1) | ES2830800T3 (enExample) |
| GB (1) | GB201518665D0 (enExample) |
| PL (1) | PL3365684T3 (enExample) |
| SG (1) | SG11201803161YA (enExample) |
| WO (1) | WO2017068371A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1206055A1 (en) | 2012-03-02 | 2015-12-31 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP2971100A1 (en) | 2013-03-13 | 2016-01-20 | Sequenom, Inc. | Primers for dna methylation analysis |
| EP3736344A1 (en) | 2014-03-13 | 2020-11-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| PL3685165T3 (pl) * | 2017-09-18 | 2022-08-08 | Santersus Ag | Sposób i urządzenie do oczyszczania krwi z krążącego pozakomórkowego dna |
| EP4215621B1 (en) | 2018-03-01 | 2025-05-28 | Epicypher, Inc. | Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes |
| EP3765638A2 (en) | 2018-03-13 | 2021-01-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Diagnostic use of cell free dna chromatin immunoprecipitation |
| CN109841265B (zh) * | 2019-02-22 | 2021-09-21 | 清华大学 | 使用片段化模式确定血浆游离核酸分子组织来源的方法和系统及应用 |
| GB201906199D0 (en) * | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
| EP3757227A1 (en) * | 2019-06-25 | 2020-12-30 | Aarhus Universitet | Cell-free chromatin immunoprecipitation (cfchip) as a measure of tumour gene expression in a sample |
| GB201912251D0 (en) | 2019-08-27 | 2019-10-09 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
| US20220290252A1 (en) * | 2019-08-27 | 2022-09-15 | Belgian Volition Srl | Method of isolating circulating nucleosomes |
| CN114829939B (zh) * | 2019-12-02 | 2025-10-21 | 比利时意志有限责任公司 | 无细胞核小体作为生物标志物的用途 |
| TW202242145A (zh) * | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
| US12053567B2 (en) | 2021-12-27 | 2024-08-06 | Santersus Ag | Method and device for removal of circulating cell free DNA |
| WO2024042210A1 (en) * | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
| GB202300607D0 (en) | 2023-01-16 | 2023-03-01 | Belgian Volition Srl | Proteins and methods for isolating circulating nucleosomes |
| TW202530419A (zh) | 2023-10-04 | 2025-08-01 | 比利時商比利時意志有限公司 | Pcr方法 |
| CN117904196B (zh) * | 2024-01-05 | 2024-07-12 | 安徽大学 | 一种非小细胞肺癌组蛋白h1.4赖氨酸乙酰化点突变细胞模型的构建及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807999A (en) | 1993-02-01 | 1998-09-15 | Mt. Sinai School Of Medicine Of The City University Of New York | Monoclonal antibody that distinguishes between phosphorylated and nonphosphorylated histone H1 and uses therefor |
| GB0319376D0 (en) * | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
| EP2496717B1 (en) | 2009-11-05 | 2017-06-07 | The Chinese University of Hong Kong | Fetal genomic analysis from a maternal biological sample |
| WO2011092715A2 (en) | 2010-01-27 | 2011-08-04 | Tata Memorial Centre | Method for in-vivo binding of chromatin fragments |
| US8981066B2 (en) | 2011-08-23 | 2015-03-17 | Buck Institute For Research On Aging | Epigenetic mechanisms related to DNA damage and aging |
| GB201115098D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201115099D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| EP2788767B1 (en) | 2011-12-07 | 2017-09-06 | Belgian Volition SPRL | Method for detecting nucleosome adducts |
| HK1206055A1 (en) * | 2012-03-02 | 2015-12-31 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
-
2015
- 2015-10-21 GB GBGB1518665.3A patent/GB201518665D0/en not_active Ceased
-
2016
- 2016-10-21 WO PCT/GB2016/053305 patent/WO2017068371A1/en not_active Ceased
- 2016-10-21 EP EP16787545.9A patent/EP3365684B1/en active Active
- 2016-10-21 US US15/768,984 patent/US10746746B2/en active Active
- 2016-10-21 CA CA3002505A patent/CA3002505A1/en active Pending
- 2016-10-21 JP JP2018520599A patent/JP6831841B2/ja not_active Expired - Fee Related
- 2016-10-21 AU AU2016341501A patent/AU2016341501B2/en not_active Ceased
- 2016-10-21 SG SG11201803161YA patent/SG11201803161YA/en unknown
- 2016-10-21 PL PL16787545T patent/PL3365684T3/pl unknown
- 2016-10-21 CN CN201680074815.1A patent/CN108603884A/zh active Pending
- 2016-10-21 EP EP20190999.1A patent/EP3798634A1/en not_active Withdrawn
- 2016-10-21 DK DK16787545.9T patent/DK3365684T3/da active
- 2016-10-21 ES ES16787545T patent/ES2830800T3/es active Active
-
2020
- 2020-07-14 US US16/929,016 patent/US20200340997A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3365684A1 (en) | 2018-08-29 |
| WO2017068371A1 (en) | 2017-04-27 |
| GB201518665D0 (en) | 2015-12-02 |
| JP6831841B2 (ja) | 2021-02-17 |
| ES2830800T3 (es) | 2021-06-04 |
| EP3365684B1 (en) | 2020-09-23 |
| SG11201803161YA (en) | 2018-05-30 |
| AU2016341501A1 (en) | 2018-05-10 |
| PL3365684T3 (pl) | 2021-05-04 |
| US10746746B2 (en) | 2020-08-18 |
| AU2016341501B2 (en) | 2022-09-08 |
| DK3365684T3 (da) | 2020-12-21 |
| US20200340997A1 (en) | 2020-10-29 |
| EP3798634A1 (en) | 2021-03-31 |
| CN108603884A (zh) | 2018-09-28 |
| JP2019500582A (ja) | 2019-01-10 |
| US20190064184A1 (en) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200340997A1 (en) | Method for the enrichment of cell free nucleosomes | |
| US20220334128A1 (en) | Method for the enrichment of circulating tumor dna | |
| US10768182B2 (en) | Method for detecting nucleosomes containing histone modifications and variants | |
| CN114901832A (zh) | 分离循环核小体的方法 | |
| JP6777757B2 (ja) | 癌検出のためのヌクレオソーム−転写因子複合体の使用 | |
| TWI726009B (zh) | 用親和純化法分析生物樣品中源自腫瘤之無細胞核小體、分離生物樣品中純化之腫瘤dna、檢測生物樣品中源自腫瘤之核小體表觀遺傳表位或在動物或人類受試者中檢測癌症之方法或包括組蛋白h1結合劑之套組之用途 | |
| HK40051192A (en) | Method for the enrichment of cell free nucleosomes | |
| HK1260172A1 (en) | Method for the enrichment of cell free nucleosomes | |
| HK1260172B (en) | Method for the enrichment of cell free nucleosomes | |
| HK40050636A (en) | Method for the enrichment of circulating tumor dna | |
| HK1243764B (en) | Method for the enrichment of circulating tumor dna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211007 |
|
| EEER | Examination request |
Effective date: 20211007 |
|
| EEER | Examination request |
Effective date: 20211007 |
|
| EEER | Examination request |
Effective date: 20211007 |